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Abstract  
Objective: Based on the flow cytometry multiparametric immunophenotyping methodology we 
studied some useful cell marker criteria needed for the practical differentiation of the chronic 
lymphocytic leukemia from other chronic limphoproliferative diseases with a leukemic component. 
Materials and Methods: The applied methodology is a four color flow cytometry multiparametric 
immunophenotyping technique using EDTA blood samples taken from 84 consecutive patients 
diagnosed with CLL through a preliminary clinical and white blood cell examination. The following 
fluorescent stained monoclonal antibodies were used: CD3, CD4, CD5, CD8, CD11c, CD19, CD20, 
CD23, CD25, FMC7 and kappa/lambda light chains.  
Results: From the 84 individuals tested, 2 out of them (2.4%) resulted with a abnormal T-cell 
population while 82 (97.6%) showed a pathological B cell line. 58 (69.1%) patients resulted with 
typical CLL markers (CD19+CD5+CD23+) while 5 (5.9%) of them presented a non typical chronic 
lymphocytic leukemia profile (CD19+CD5+CD23-). 19 (22.6%) out of patients displayed an 
abnormal CD19+CD5- B cell population. A statistically significant correlation was found between the 
clinical stage of CLL and the positivity for the CD38 marker (p=0.04).  
Conclusion: Flow cytometry immunophenotyping is a fundamental examination for the final 
diagnosis of chronic lymphocytic leukemia. The expression of CD38+ in CLL patients stands for a 
more advanced clinical stage. 
  
 
 
 
Introduction 
Chronic lymphocytic leukemia (CLL) is the 
most common type of leukemia in adults [1]. It is 
generally accepted that any lymphocytosis superior to 
5000/mm
3
 in an adult person, and without any other 
evident cause, must raise the suspicion of a CLL 
diagnosis [2]. The leukemia cells found in the CLL 
blood smear are characteristically small, mature 
lymphocytes with a narrow border of cytoplasm and a 
dense nucleus lacking discernible nucleoli and having 
partially aggregated chromatin [3]. The patients 
presented with clinical and laboratory signs evoking 
CLL must be thoroughly checked if they have or not 
some other chronic lymphoproliferative disease 
(CLPD) that can masquerade as CLL, such as hairy 
cell leukemia, leukemic manifestations of mantle cell 
lymphoma, marginal zone lymphoma, splenic 
marginal zone lymphoma with circulating villous 
lymphocytes, or follicular lymphoma [4, 5]. In order to 
achieve this, it is essential to evaluate the blood 
count, the blood smear, the detailed 
immunophenotype of the concerned lymphoid cells 
and often additional immunohistological or cytogenetic 
studies are also needed [6, 7]. The purpose of this 
study was to evaluate the impact of the application of 
the multiparametric flow cytometry immunopheno-
typing (FCI) as a standard testing methodology for the 
confirmation or exlusion of CLL diagnosis in a 
population of 84 consecutive Albanian patients in 
whom the CLL diagnosis has been set in advance on 
the basis of clinical, blood cell counting and peripheral 
blood smear cytology data. We also aimed to 
determine the contribution of FCI for the evaluation of 
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the staging and disease progression among the CLL 
patients. 
 
Materials and Methods 
Patients 
This study was carried out at the Laboratory 
of Immunology and Histocompatibility of the University 
Hospital Center “Mother Teresa” of Tirana, Albania 
during the time interval January 2011 to december 
2012. 
It included 84 consecutive patients previously 
diagnosed with CLL through a preliminary clinical 
evaluation and a standard blood cell examination. The 
patient blood samples were sent to our laboratory 
from the Department of Hematology of the “Mother 
Teresa” University Hospital Center of Tirana in order 
to confirm the CLL diagnosis.  
The age of the patients ranged from 40 to 85 
years (mean: 61.2 years). 55 (65.5%) of them were 
males and 29 (34.5%) females. The blood samples 
were examined at our laboratory immediately after 
their arrival and the immunophenotypic diagnosis was 
established without any previous knowledge about the 
clinical or hematological data. The patient files were 
studied retrospectively in order to compare the flow 
cytometry results with the clinical data. The clinical 
data were used to classify the patients into different 
clinical CLL stages as following the Rai classification 
[8]. The patients who presented only a blood 
lymphocytosis superior to 5000/mm
3
 and/or a bone 
marrow lymphocytosis (lymphoid cells >30%) were 
defined as having low-risk disease or Rai stage 0. 
Patients with lymphocytosis, enlarged nodes in any 
site, splenomegaly and/or hepatomegaly were defined 
as having intermediate-risk disease (Rai stage I or 
stage II). High-risk disease included Rai stage III and 
IV patients with disease-related anemia (as defined by 
a hemoglobin level <11 g/dL) or thrombocytopenia 
(defined by a platelet count < 100.000 mm
3
). 
 
Methods 
The applied methodology was a four color FCI 
technique using EDTA blood samples that were 
examined in an EPICS-XL Beckman-Coulter flow 
cytometer. The samples were processed through a 
“no wash, staining and lysis” procedure using the 
Optilyse reagent (Beckman-Coulter, California, USA) 
as recommended from the manufacturer. A “lysing, 
wash and staining” procedure was applied only for 
kappa and lambda light chain markers. The FCI was 
carried out through a gating strategy based on the 
side scatter (SS) versus CD45 white cell scattering 
(Fig. 1). The following stained monoclonal antibodies 
directed to the membrane cell marker antigens were 
used for the white blood cell staining with this method: 
CD3-PC5, CD4-PE, CD5-PE, CD8-ECD, CD11c-PE, 
CD19-PC5, CD20-PE, CD23-ECD, CD25-ECD, 
CD38-PC5. The membrane cell marker FMC7 and 
kappa/lambda immunoglobulin light chains were 
examined through a two color cell staining and by 
gating on the lymphocyte population as following a SS 
versus forward scatter (FS) cell distribution. If more 
than 20% of the gated cell population resulted positive 
for a given stained monoclonal antibody it was 
considered as positive for the respective cell marker. 
The Fischer exact test was used to evaluate the 
differences between the categorical variables. 
 
Figure 1: Flow cytometry CD45 versus side scatter (SS) in CLL cell 
differentiation. 
 
Results 
Diagnostic differentiation of the abnormal 
lymphoid cell population through FCI 
The cell marker positivity results observed on 
the abnormal cell populations of all the patients 
studied is presented in Table 1.  
Table 1: The cell markers studied and their positivity rate on 
the leukemic cells of all the patients examined. 
Leukemic cell  markers studied 
(No.of patients tested) 
Marker positivity 
No.of positive patients (%) 
CD3     ( 84 ) 2 (2.4%) 
CD4     ( 84 ) 2 (2.4%) 
CD5     ( 84 ) 65 (77.3%) 
CD8     ( 84 ) 1 (1.2%) 
CD11c ( 20 ) 3 (15.0%) 
CD19   ( 84 ) 82 (97.6%) 
CD20   ( 84 ) 45 (53.6%) 
CD23   ( 84 ) 63 (75.0%) 
CD25   ( 22) 3 (13.6%) 
CD38   (35 ) 18 (51.4 %) 
kappa/lambda light chains (23 ) 16 (69.6%) 
FMC-7   ( 18 ) 3 (16.6%) 
 
From all the 84 individuals tested, 2 of them 
(2.4%) resulted with an abnormal T cell population 
(CD3+, CD4+ and/or CD8+) while the resting 82 
(97.6%) of patients showed a pathological B cell line. 
From these, 58 (69.0%) out of all patients resulted 
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with a typical CLL cell marker profile 
(CD19+CD5+CD23+) whilst 5 (6 %) of them showed a 
non typical (CD19+CD5+CD23-) CLL profile. An 
abnormal CD19+CD5- B cell population has been 
observed in 19 (22.6%) out of patients. Among these, 
3 (3.6%) resulted with hairy cell leukemia (HCL) 
markers (CD19+CD5-CD23-CD11c+FMC-7+). In 
Table 2 are shown the results of the CD20 marker 
positivity among the B cell CLPD diagnosed according 
to their classification after the FCI examination. The 
positivity rate of this cell marker has been found 
higher in both non typical CLL and CD19+CD5- 
patient subgroups in contrast to the typical CLL 
patients but a statistically significant difference was 
found only between the typical CLL and the 
CD19+CD5- group of patients (P < 0.001).  
Table 2: CD20 marker positivity among the B cell CLPD 
according to their classification after the FCI examination. 
 Typical CLL Atypical CLL B-CLPD (CD5-) 
CD cell 
marker 
positivity 
CD19+CD5+CD23+ 
(n = 58) 
CD19+CD5+CD23- 
(n = 5) 
CD19+CD5-CD23- 
(n=19) 
CD20 +    44,8%   20 %   93,7% 
CLL = Chronic lymphocytic leukemia; B-CLPD = B-cell chronic lymphoproliferative 
diseases. 
 
Correlation studies of the immunophenotypic 
markers with the disease progression 
The classification according to RAI 
stratification of the typical CLL patients of our series is 
shown in Table 3.  
Table 3: Classification of typical CLL patients according to the 
clinical stages by RAI. 
CLL Stage                                      Number of patients (%) 
0 0 (0 %) 
I 6 (10.3%) 
II 18 (31.03 %) 
III 20 (34.4 %) 
IV 14 (24.13 %) 
Total 58 (100 %) 
 
We investigated also for the presence of any 
association between the CD38, CD20 and 
immunoglobulin light chain membrane cell markers 
and the disease progression (Table 4). A statistically 
significant association was found only between the 
CLL clinical stages and the positivity for the CD38 
marker (P = 0.04). 
Table 4: Correlation between the positivity of the cell markers 
CD38, CD20, kappa/lambda light chain and the disease stages 
among the patients with typical CLL immunophenotypic 
profile. 
Marker positivity Stage 0, I, II Stage  III - IV P – Value 
CD38+ 2 (25%) 14 (70%) P = 0.04 
 CD20+ 12 (50%) 14 (41.1%) P = 0.60 
light chain+ 
 
3 (75%) 8 (72.7%) P = 1.00 
 
 
Discussion 
Although it is well known that CLL is the more 
common cause of leukemia among adults older than 
50 years, many other malignant CLPD can mimick 
CLL when they are accompanied by a leukemic cell 
component (9). In addition to the classical cytology, 
several diagnostic tools such as FCI, 
immunohistochemistry or cytogenetic and molecular 
biology methods are needed in order to establish a 
precise CLPD diagnosis [10, 11]. However, in health 
care settings with limited financial and technological 
resources, it is often difficult to implement all these 
methods concomitantly, due to their high cost and 
also the need for well trained and skilled personnel 
Taking into account the fact that multiparametric FCI 
has been shown as a practical, rapid and powerful 
tool for the diagnosis of malignant hemopathies, we 
studied the impact of the implementation of this 
methodology into the more precise diagnosis of 84 
consecutive patients sent at our laboratory with a 
preliminary CLL diagnosis established on the basis of 
their clinical and cytological data.  
From the 84 consecutive patients with a 
preliminary CLL diagnosis, 2 of them (2.4%) resulted 
with a blood T-cell leukemic component. Some 
authors do not accept the diagnosis of T-cell CLL and 
according to them the most likely diagnosis in this 
situation is the prolymphocytic T-cell leukemia or the 
Sezary síndrome with a leukemic component [12-14]. 
The presence of the marker CD5 is a prerequisite 
condition for the diagnosis of CLL [15, 16]. For this 
reason we divided the patients presenting an 
abnormal B cell population into the CD5+ and CD5- 
subgroups. Into the CD5+ subgroup were included 63 
individuals or 76.8% of all patients initially diagnosed 
as CLL.  
According to the literature reports the 
leukemic CLL B cells typically express the three 
characteristic markers CD19+, CD5+ and CD23+ [17, 
18]. In our study they accounted for 92.0% of CD19+ 
CD5+ patients or 69.1% of all the patients studied. So, 
the typical CLL in our study constitutes no more than 
70% of all our patients presenting a CLPD associated 
with a leukemic blood cell population. The patients 
with an abnormal CD5+ CD19+ CD23- cell population 
constituted 5.9% of all the individuals studied or 8% of 
CD19+ CD5+ patients. Like other authors we named 
this group as atypical CLL [19] in contrast with the 
typical CLL patients who show the CD5+ CD19+ 
CD23+ immunophenotype.  
The CD5+CD19+CD23- immunophenotypic 
profile is evocative also for the mantle cell lymphoma 
(MCL), the chronic prolymphocytic leukemia or 
eventually another B –cell CLPD [20, 21]. The 
accurate MCL diagnosis requires a further and more 
detailed imunohistochemistry and cytogenetic study 
including other markers such as Cyclin D1 or 11, 14 
chromosome translocations [22, 23]. MCL abnormal 
cells often express also the FMC7 marker (24). In our 
series the FMC7 marker resulted positive in one CD5 
+ CD19 + CD23- patient who was later confirmed with 
the MCL diagnosis.  
A CD19+CD5- immunophenotyping profile 
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was found in 22.6% of our patient group. This profile 
suggests the presence of a non-CLL B-cell CLPD 
such as hairy cell leukemia (found in 3.6% of our 
patients), or any other non-Hodgkin B-cell lymphoma 
type with a leukemic component (follicular lymphoma, 
marginal zone lymphomas or other large cell 
lymphomas) that accounted for 19% of our patient 
population.  
The CD20 marker is weakly expressed or 
even absent in typical CLL cells [25]. In our study the 
CD20 positivity rate was 20% at the typical CLL cells 
and 46.6% at the atypical CLL cells. We also 
observed a highly significant CD20 positivity at the 
CD5+CD19- patient subgroup compared with the 
CD19+ CD5+ patients. In this regard, the CD20 can 
serve as an immunophenotipic marker for the 
differentiation of typical from atypical CLL, and also 
from any other type of non-Hodgkin's lymphoma.  
Another interesting marker for the study of 
CLL is CD38 that has been associated with a more 
advanced disease progression and a rather poor 
prognosis [27-29]. We found that 70% of 
CD5+CD19+CD23+ positive patients expressing the 
CD38+ marker belonged to the disease stages III-IV, 
while 75% of them who did not express this marker 
belonged to the stages 0-I-II (P = 0.04). According to 
the reports from the United States of America and 
European countries most of the patients with an initial 
CLL diagnosis are currently classified at the initial 0, I 
and II disease stages [30]. In this regard it is worth 
mentioning that we have encountered in our patients a 
more frequent presence of disease stages III and IV 
(69.0%) compared to the stages 0, I and II (31.0%). 
This seems to be related to a rather advanced stage 
of the disease at the time of diagnosis.  
We can conclude that FCI is a fundamental 
laboratory examination for the final CLL diagnosis and 
this diagnosis can not be established without a 
detailed flow cytometry immunophenotyping profile of 
the leukemic cells. Additional methods such as 
immunochemistry or cytogenetic studies must be 
applied when a conclusive diagnosis can not be 
achieved through FCI. 
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